How Eli Lilly’s $1.5B Calytrix Deal & Adolescent Obesity Strategy Drive Future Growth
El Lilly expands into niche oncology and adolescent obesity, acquiring Calytrix Bio’s biparatopic platform and advancing Zepbound with 18.5% BMI loss—boosting high‑margin specialty therapeutics and diversifying revenue.
4 minutes to read









